Physician profile
Ali Piper
NPI 1396009031
$651.28
in general payments reported to CMS, 2019-2025
16 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $24.99 · 2022: $192 · 2023: $87.34 · 2024: $33.22 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $180.39 | 2022 | |
| Inspire Medical Systems, INC. | $87.34 | 2023 | Inspire |
| Amgen INC. | $64.94 | 2025 | Tezspire, Tavneos |
| Sunovion Pharmaceuticals INC. | $49.83 | 2019 | |
| Resmed Corp | $48.15 | 2025 | |
| Jazz Pharmaceuticals INC. | $43.04 | 2019-2025 | |
| Abiomed | $38.29 | 2025 | |
| Janssen Pharmaceuticals, INC | $24.65 | 2019-2022 | |
| Grifols USA, LLC | $18.25 | 2024 | Prolastin-C Liquid |
| Genzyme Corporation | $16.35 | 2025 | |
| Pfizer INC. | $14.97 | 2024 | |
| Glaxosmithkline, LLC. | $14.31 | 2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $13.96 | 2020 | |
| Viatris Specialty LLC | $13.56 | 2025 | Yupelri |
| Genentech USA, INC. | $12.22 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Piper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.